Accelerating the manufacturing of HIV Env protein vaccines for early phase clinical evaluation
This commentary discusses the benefits in terms of time savings and reduced costs of goods in using transient electroporation and immuno-affinity purification as an alternative to the traditional manufacturing approaches for the CGMP manufacturing of HIV Envelope protein immunogens for use in invest...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01169-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226644747714560 |
|---|---|
| author | Michael N. Pensiero |
| author_facet | Michael N. Pensiero |
| author_sort | Michael N. Pensiero |
| collection | DOAJ |
| description | This commentary discusses the benefits in terms of time savings and reduced costs of goods in using transient electroporation and immuno-affinity purification as an alternative to the traditional manufacturing approaches for the CGMP manufacturing of HIV Envelope protein immunogens for use in investigational clinical studies. The companion manuscript by Bale et al. describes in detail this approach for CGMP manufacture and analytical evaluation of a near-native HIV envelope timer. |
| format | Article |
| id | doaj-art-5a2f5a35e5174489bb47b95c2ba398ed |
| institution | Kabale University |
| issn | 2059-0105 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-5a2f5a35e5174489bb47b95c2ba398ed2025-08-24T11:06:35ZengNature Portfolionpj Vaccines2059-01052025-08-011011210.1038/s41541-025-01169-yAccelerating the manufacturing of HIV Env protein vaccines for early phase clinical evaluationMichael N. Pensiero0National Institute of Allergy and Infectious DiseasesThis commentary discusses the benefits in terms of time savings and reduced costs of goods in using transient electroporation and immuno-affinity purification as an alternative to the traditional manufacturing approaches for the CGMP manufacturing of HIV Envelope protein immunogens for use in investigational clinical studies. The companion manuscript by Bale et al. describes in detail this approach for CGMP manufacture and analytical evaluation of a near-native HIV envelope timer.https://doi.org/10.1038/s41541-025-01169-y |
| spellingShingle | Michael N. Pensiero Accelerating the manufacturing of HIV Env protein vaccines for early phase clinical evaluation npj Vaccines |
| title | Accelerating the manufacturing of HIV Env protein vaccines for early phase clinical evaluation |
| title_full | Accelerating the manufacturing of HIV Env protein vaccines for early phase clinical evaluation |
| title_fullStr | Accelerating the manufacturing of HIV Env protein vaccines for early phase clinical evaluation |
| title_full_unstemmed | Accelerating the manufacturing of HIV Env protein vaccines for early phase clinical evaluation |
| title_short | Accelerating the manufacturing of HIV Env protein vaccines for early phase clinical evaluation |
| title_sort | accelerating the manufacturing of hiv env protein vaccines for early phase clinical evaluation |
| url | https://doi.org/10.1038/s41541-025-01169-y |
| work_keys_str_mv | AT michaelnpensiero acceleratingthemanufacturingofhivenvproteinvaccinesforearlyphaseclinicalevaluation |